YD Bio (YDES) Current Leases (2024 - 2025)
YD Bio (YDES) posted quarterly Current Leases of $6.8 billion for Q4 2025, down 59.21% year-over-year from $16.6 billion in Q4 2024, and up 42899627.28% quarter-over-quarter from $15767.0 in Q2 2025.
YD Bio (YDES) Current Leases (2024 - 2025) Analysis & Trends
YD Bio (YDES) has reported Current Leases for 2 consecutive years, with $6.8 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases fell 59.21% year-over-year to $6.8 billion; the TTM figure through Dec 2025 stood at $6.8 billion (down 59.21% YoY), while the FY2025 annual figure was $6.8 billion, down 59.21% from the prior year.
- Current Leases improved to $6.8 billion in Q4 2025 per YDES's latest filing, from $15767.0 in the prior quarter.
- Across five years, Current Leases topped out at $16.6 billion in Q4 2024 and bottomed at $15767.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | - |
| 10 | YD Bio | 299.57 Mn | 293.56 Mn | - | 6.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.76 Bn |
| Jun 30, 2025 | 15,767.00 |
| Dec 31, 2024 | 16.58 Bn |